105362-06-9 Usage
Uses
Used in Medicinal Chemistry Research:
4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-thiazol-2-ylamine is used as a research tool for the development of new pharmaceuticals due to its structural features that are conducive to drug design. Its presence in compounds with known biological activities suggests that it may contribute to the creation of novel therapeutic agents.
Used in Drug Design and Development:
In the pharmaceutical industry, 4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-thiazol-2-ylamine is used as a molecular scaffold for designing drugs with potential applications in treating various diseases and conditions. Its structural attributes, including the thiazole and benzodioxin rings, are known to enhance the biological activity of compounds, making it a key component in the synthesis of new medicinal agents.
Further exploration of 4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-thiazol-2-ylamine's properties and pharmacological activities is necessary to fully understand its utility in medicinal chemistry and to unlock its potential in the development of innovative treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 105362-06-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,3,6 and 2 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 105362-06:
(8*1)+(7*0)+(6*5)+(5*3)+(4*6)+(3*2)+(2*0)+(1*6)=89
89 % 10 = 9
So 105362-06-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H10N2O2S/c12-11-13-8(6-16-11)7-1-2-9-10(5-7)15-4-3-14-9/h1-2,5-6H,3-4H2,(H2,12,13)
105362-06-9Relevant academic research and scientific papers
Studies of arylthiazole oxamates in relation to oral antiallergic activity
Cousse,Mouzin,Bonnaud,Tarayre,Couzinier
, p. 1391 - 1393 (2007/10/02)
25 arylthiazole oxamate derivatives were synthesized and examined for antiallergic activity in the rat passive cutaneous anaphylaxis assay. These compounds were prepared by treatment of the appropriate bromoacetophenone with thioureas to give arylaminothiazoles. Further condensation with alkyloxalyl chloride gave the arylthiazolyl oxamates. Several derivatives showed a 70% inhibition at 5 mg/kg p.o. p-Alkoxy substitution on the phenyl ring resulted in enhanced activity while N-alkyl substitution on the nitrogen amide function inhibited the activity. Ethyl-N-(4-p-methoxyphenyl)-2-thiazolyl oxamate (tioxamast, F-1865) was selected for clinical studies.
